Developing new treatments for Alzheimer's disease: The who, what, when, and how of biomarker-guided therapies

Constantine G. Lyketsos, Christine A. Szekely, Michelle M Mielke, Paul B. Rosenberg, Peter P. Zandi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.

Original languageEnglish (US)
Pages (from-to)871-889
Number of pages19
JournalInternational Psychogeriatrics
Volume20
Issue number5
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Alzheimer Disease
Biomarkers
Therapeutics
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Clinical Trials

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Aging
  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Developing new treatments for Alzheimer's disease : The who, what, when, and how of biomarker-guided therapies. / Lyketsos, Constantine G.; Szekely, Christine A.; Mielke, Michelle M; Rosenberg, Paul B.; Zandi, Peter P.

In: International Psychogeriatrics, Vol. 20, No. 5, 10.2008, p. 871-889.

Research output: Contribution to journalArticle

Lyketsos, Constantine G. ; Szekely, Christine A. ; Mielke, Michelle M ; Rosenberg, Paul B. ; Zandi, Peter P. / Developing new treatments for Alzheimer's disease : The who, what, when, and how of biomarker-guided therapies. In: International Psychogeriatrics. 2008 ; Vol. 20, No. 5. pp. 871-889.
@article{fb02432d83f14e78b1e71b551d9a62dc,
title = "Developing new treatments for Alzheimer's disease: The who, what, when, and how of biomarker-guided therapies",
abstract = "This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.",
author = "Lyketsos, {Constantine G.} and Szekely, {Christine A.} and Mielke, {Michelle M} and Rosenberg, {Paul B.} and Zandi, {Peter P.}",
year = "2008",
month = "10",
doi = "10.1017/S1041610208007382",
language = "English (US)",
volume = "20",
pages = "871--889",
journal = "International psychogeriatrics / IPA",
issn = "1041-6102",
publisher = "Cambridge University Press",
number = "5",

}

TY - JOUR

T1 - Developing new treatments for Alzheimer's disease

T2 - The who, what, when, and how of biomarker-guided therapies

AU - Lyketsos, Constantine G.

AU - Szekely, Christine A.

AU - Mielke, Michelle M

AU - Rosenberg, Paul B.

AU - Zandi, Peter P.

PY - 2008/10

Y1 - 2008/10

N2 - This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.

AB - This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.

UR - http://www.scopus.com/inward/record.url?scp=50149118691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50149118691&partnerID=8YFLogxK

U2 - 10.1017/S1041610208007382

DO - 10.1017/S1041610208007382

M3 - Article

C2 - 18498669

AN - SCOPUS:50149118691

VL - 20

SP - 871

EP - 889

JO - International psychogeriatrics / IPA

JF - International psychogeriatrics / IPA

SN - 1041-6102

IS - 5

ER -